We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

qPCR Assay Identifies Melanoma Patients With Low-Risk Tumor That Could Avoid Invasive Biopsy

By LabMedica International staff writers
Posted on 06 Sep 2022
Print article
Image: SkylineDx has announced the commercial launch of Merlin Assay as CE-IVD kit in Europe (Photo courtesy of Pexels)
Image: SkylineDx has announced the commercial launch of Merlin Assay as CE-IVD kit in Europe (Photo courtesy of Pexels)

Melanoma is an aggressive type of skin cancer. Sentinel lymph node biopsy (SLNB) is an invasive surgical procedure used to determine metastatic spread of the cancer for staging purposes. In approximately 80% of surgeries, the biopsy comes back negative for metastasis, where it does not further impact the patient pathway. Now, a new test provides a more personalized insight on the metastatic propensity of the tumor, identifying patients with a low-risk tumor that could avoid the surgery.

SkylineDx’s (Rotterdam, The Netherlands) Merlin Assay identifies melanoma patients that have a low risk for nodal metastasis and therefore can safely forgo a SLNB surgery. The CE-IVD device is based on a well-established qPCR method that can easily run in molecular diagnostic laboratories. Merlin Assay uses the CP-GEP model, a powerful proprietary algorithm that calculates the risk of metastasis in a patient's sentinel lymph nodes. The model is able to calculate risk on an individual basis through a combination analysis of eight genes from the patient's primary tumor, the tumor thickness and the patient's age; and has been analytically and clinically validated. SkylineDx has announced the commercial launch of Merlin Assay as CE-IVD distributable test kit in Europe.

"Launching Merlin Assay as CE-IVD marked manual kit in Europe signifies a major milestone in making our diagnostic solutions available to patients globally," said Dharminder Chahal, CEO SkylineDx.

Related Links:
SkylineDx 

Gold Supplier
POC Test Reader
NycoCard READER II
New
HPLC System
Jasper HPLC System
New
POC Pathogen Detection & Gene Expression System
Sal6830 Mobile Workstation
New
1,5-AG Test
1,5-Anhydroglucitol Test Kit

Print article
IIR Middle East

Channels

Technology

view channel
Image: OneDraw Blood Collection Device significantly reduces obstacles for drawing blood (Photo courtesy of Drawbridge Health)

Near Pain-Free Blood Collection Technology Enables High-Quality Testing

Blood tests help doctors diagnose diseases and conditions such as cancer, diabetes, anemia, and coronary heart disease, as well as evaluate organ functionality. They can also be used to identify disease... Read more

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.